Shares of Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $7.1620, but opened at $6.70. Oxford BioMedica shares last traded at $6.70, with a volume of 3,000 shares trading hands.
Analysts Set New Price Targets
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company currently has a consensus rating of “Hold”.
Get Our Latest Analysis on OXBDF
Oxford BioMedica Stock Performance
About Oxford BioMedica
Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.
Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.
Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.
Further Reading
- Five stocks we like better than Oxford BioMedica
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
